What is NexCure?
NexCure is at the forefront of revolutionizing CAR-T and other advanced therapeutic treatments by delivering them in community, outpatient settings. The company's innovative platform translates hospital-grade clinical rigor into scalable, community-based outpatient clinics. By integrating AI-powered patient selection, remote monitoring, and standardized clinical protocols, NexCure ensures that patients receive safe, compassionate, and personalized treatment, thereby redesigning the entire therapeutic delivery ecosystem.
How much funding has NexCure raised?
NexCure has raised a total of $19M across 1 funding round:
Series A
$19M
Series A (2026): $19M with participation from Oncology Ventures, Cencora, and RA Capital Management
Key Investors in NexCure
Oncology Ventures
Oncology Ventures is dedicated to investing in healthcare data companies that address significant challenges in cancer care, focusing on early detection, patient navigation, and AI-powered treatment optimization. The company aims to improve the fragmented and costly U.S. oncology system by funding technologies that enhance evidence-based care.
Cencora
Established in 2023 and headquartered in Pennsylvania, Cencora is a leading pharmaceutical solutions organization centered on improving the lives of people and animals everywhere.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies, including those developing drugs, medical devices, diagnostics, and research tools. Their mission is to partner with innovators to bring ideas from the lab to the clinic, ultimately improving patient lives.
What's next for NexCure?
With this major enterprise-level funding, NexCure is poised for significant expansion and further development of its groundbreaking platform. The strategic investment will likely fuel the scaling of its outpatient clinic network, enhance its AI capabilities for patient selection and monitoring, and broaden its reach to more patients requiring advanced therapies. This capital infusion signals confidence in NexCure's model to make cutting-edge treatments more accessible and efficient, positioning the company for substantial growth in the evolving landscape of personalized medicine.
See full NexCure company page
